All In Biotech

Drug Trial Radar · NCT01364064

Conventional Adjuvant Temozolomide With Dose Intensive Temozolomide in Patients With Newly Diagnosed Glioblastoma

Last checked: Nov 20, 2026Latest source record: Feb 25, 2016 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 1,153 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

1,153

Actual

Start

Jan 2007

Primary completion

Jun 2008

Study completion Jun 2008

Sponsor

Lead sponsor
King Faisal Specialist Hospital & Research CenterAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Radiation Therapy Oncology Group
First posted
Jun 2, 2011

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
Who can join
All sexes
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a Phase III Trial Comparing Conventional Adjuvant Temozolomide with Dose Intensive Temozolomide in Patients with Newly Diagnosed Glioblastoma.

Conditions

  • Glioblastoma

Interventions

  • TMZDrug

    Comparing conventional adjuvant Temozolomide with dose intensive Temozolomide

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. safety and efficacyTime frame: 5 years

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.